Most investors would like a "do over."

They look back on certain investments and wish they'd never heard of, much less put money in them. Sure things like your good friend's invention that would make beer in one day from water and weeds. Or your brother's idea of selling real estate on Saturn. Everyone has their own stories. Mine are usually related to private investments in the medical device field or biotech, though I did have one out of Florida that made a "pig" that ran through oil pipelines to check on their safety. After meeting the founder who looked more like a used car salesman that caught a great sale on polyester suits, I should have known better right then. But I didn't.

Analyst Upgrades

• Polo Ralph Lauren (RL) to buy from hold at Citigroup.
• Qualcomm (QCOM) to buy from neutral at Roth Capital.
• Walgreen (WAG) to conviction buy from neutral at Goldman.
• Rockwell (ROK) to outperform from neutral at Credit Suisse.
• Carnival (CCL) to buy from hold at Deutsche Bank.
• SunTrust (STI) and TD Bank (TD) to outperform from market perform at Keefe Bruyette.
• Hawaiian Electric (HE) to outperform from neutral at RW Baird.
• Essex Property Trust (ESS) to outperform from neutral at Macquarie.
• Amgen (AMGN) to neutral from underperform at BofA/Merrill.

Markets were mixed into the closing bell today and down to the wire as indexes fluctuated between positive and negative. The FOMC kept rates at zero and committed to ongoing quantitative easing measures, which includes reinvesting monies coming in from its existing securities portfolio. Retail and electronics were weak based on an earnings disappointment.

Here were today's unofficial closing bell levels:

Dow Jones 11,476.62 +48.06 (0.42%)
S&P 500 1,241.58 +1.12 (0.09%)
Nasdaq 2,627.72 +2.81 (0.11%)

Top Analyst Upgrades & Downgrades

Late Monday, Amgen (AMGN) unveiled positive results for its bone drug, denosumab. A clinical study of 1,432 men with hormone refractory prostate cancer revealed that denosumab, which is also known as Xgeva, improved bone metastasis-free survival by 4.2 months. However, the overall survival rate was comparable to a placebo group.

Denosumab is already used to treat osteoporosis under the brand name Prolia, and has been approved under the brand name Xgeva for the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors. The drug has not yet been approved for the prevention of SREs in multiple myeloma patients.

Analyst Upgrades

• Amgen (AMGN) to overweight from neutral at Piper Jaffray.
• Goodrich Petroleum (GDP) to outperform from market perform at Wells Fargo.
• Tutor Perini (TPC) to buy from neutral at UBS.
• Covidien (COV) to buy from neutral at Goldman.
• Sara Lee (SLE) and Comcast (CMCSA) to outperform from market perform at Bernstein.
• Research In Motion (RIMM) to outperform from sector perform at FBN Securities.

Analyst Upgrades

• Goldman upgraded Jones Lang LaSalle (JLL) to buy from neutral.
• Credit Suisse upgraded Pulte Group (PHM) to neutral from underperform. Note that Citigroup downgraded the stock.
• Ameristar Casinos (ASCA) was upgraded to neutral from sell at Merriman.
• Citigroup upgraded Kimco Realty (KIM) to hold from sell.
• Mistras (MG) was upgraded to buy from hold at KeyBanc.
• Devon Energy (DVN) was upgraded to outperform from neutral at Macquarie.
• Garmin (GRMN) was upgraded to outperform from sector perform at PacCrest.

Analyst Upgrades

• Soleil upgraded Hologic (HOLX) to buy from hold on expectations the company's next-generation breast tomosynthesis instrument is likely to receive FDA approval. The firm raised its target price for shares to $20 from $16.
• ING Group upgraded Total (TOT) to buy from hold.
• BofA/Merrill raised Medicis (MRX) to neutral from underperform.
• CPFL Energia (CPL) was upgraded to buy from hold at Deutsche Bank.

Analyst Upgrades

• Oppenheimer upgraded Teva (TEVA) to outperform from perform. The firm expects the company to generate strong 2H10 earnings and thinks the competition created by Novartis's (NVS) Gilenia will be limited.
• Citigroup upgraded Celanese (CE) to buy from hold, citing valuation and the company's move to add assets in China, as well as possible takeover interest.
• Needham raised Stereotaxis (STXS) to buy from hold as the firm thinks that strong clinical data recently announced by the company could result in faster adoption rates of its robotic surgery.
• BMO Capital upgraded Smurfit-Stone Container (SSCC) given strength in the containerboard market.
• Melco Crown (MPEL) was upgraded to buy from neutral at UBS.
• Goldman Sachs raised Temple-Inland (TIN) to buy from neutral.
• Barclays upgraded Lloyds Banking (LYG) to equal weight from underweight.

Analyst Upgrades

• Deutsche Bank upgraded Smurfit-Stone (SSCC) to buy from hold after raising its estimates for containerboard names and upped its target for shares to $28 from $22. The firm also raised its price target for International Paper (IP) to $38 from $32, for Packaging Corp. (PKG) to $33 from $28, for Temple-Inland (TIN) to $31 from $28, for Greif (GEF) to $67 from $65, and for Rock-Tenn (RKT) to $70 from $65. All stocks are buy rated.
• ThinkEquity upgraded VMware (VMW) to buy from hold and has a $90 price target on the stock. The firm expects VMware to benefit from increased virtual infrastructure adoption and improving vSphere solutions.
• Needham upgraded Cavium Networks (CAVM) to strong buy from buy, citing the recent pullback in shares following Cisco's (CSCO) cautious commentary. The firm has a $37 target on the stock.
• Intercontinental Exchange (ICE) was upgraded to outperform from neutral at Credit Suisse.
• MedAssets (MDAS) was upgraded to buy from hold at Auriga.
• Brookfield Properties (BPO) was upgraded to buy from hold at Citigroup.

Shares of biotech giant Amgen, Inc. (AMGN) are trading slightly higher in after hours trading this afternoon after the company delivered better than expected earnings for its second quarter.

Going into this afternoon's earnings report, analysts had been expecting to see Amgen report $1.30 per share, but the company was able to beat out analyst estimates by reporting an actual $1.38 for the quarter.

Health care stocks are seen as low-risk investments by many stock market investors. After all – folks will always get sick, right? While that may be the case, it's an oversimplification to say that all health care stocks then have a built in customer base. The fact of the matter is that the health care industry has seen a big shakeup in the wake of Obama's health care reform bill and not all stocks in this sector are adapting well.

To keep your portfolio in perfect health, here are three big-name health care blue chips to sell now.

Amgen (AMGN - option chain) shares are rising today after the company said this morning the Food and Drug Administration has agreed to a priority review for Denosumab, its new skeletal drug. The FDA will decide whether to approve the drug by November 18. If you think that the stock won't fall by too much in the coming months, then now could be a good time to look at a bullish hedged trade on AMGN.

AMGN opened this morning at $52.46. So far today the stock has hit a low of $50.32 and a high of $64.76. As of 12:15, AMGN is trading at $53.00 up 0.83 (1.6%). The chart for AMGN looks bullish and S&P gives AMGN a positive 4 STARS (out of 5) buy ranking.

It appears that financial institutions, drug makers and oil companies have caught the attention of traders today -- at least, that's what they're searching for.

If you want to know what stocks traders are interested in right now at this very second, you need look no further than what's hot in Google.

Here's what's hot today.

Amgen (AMGN - option chain) shares are rising today after the Food & Drug Administration granted approval for its osteoporosis treatment Prolia two months earlier than expected. The company forecast revenue from the treatment of $115 million in 2010, $862 million in 2011, and $2.4 billion for 2013. If you think that the stock won't fall by too much in the coming months, then now could be a good time to look at a bullish hedged trade on AMGN.

AMGN opened this morning at $53.55. So far today the stock has hit a low of $53.31 and a high of $55.35. As of 12:30, AMGN is trading at $55.05 up $4.29 (8.5%). The chart for AMGN looks bullish and S&P gives AMGN a positive 4 STARS (out of 5) buy ranking.

A lot of investors think Amgen (AMGN) is a great next-generation biotech company. Wrong. Amgen was a decent last-generation biotech company.

It's terribly managed outfit living on EPO drugs for dialysis and oncology patients. True, it has a billion dollar (actually more) drug, Neupogen, but it could be subject to generic competition in the United States from TEVA within two years.